The new bottleneck

So now, the bottleneck has shifted. All these diverse new targets have slammed into the next stages of the process: target validation and hit identification. Both of these stages rely on critical-path functions that require running experiments in the wet lab:

Cell sciences

Target validation should be done with models that are as clinically relevant as possible. For in vitro work, these would ideally be patient-derived cell lines, made into organoids of the most relevant tissue type for that indication. This is exceptionally hard to achieve with predictable timelines and levels of investment.